04.10.23
Leading mass market skincare brand No7 this week is rolling out Future Renew Damage Reversal, which scientists contend represents one of the biggest developments in the brand’s history.
The line centers around a breakthrough super peptide created by No7 and the University of Manchester in the UK. The No7 team conducted blind clinical trials on the novel ingredient that No7 R&D contends “biohacks” the skin’s own natural repair process. The matrix-derived peptide blend contains two brand-new chemical entities, a patent-pending world-first technology that cannot be found in any other product, according to the brand.
Advanced mathematical modeling enabled the development of a potent delivery system that improves peptide penetration; the science has been confirmed through research with the University of Nottingham, according to No7.
The first three will hit shelves on April 12; the SPF will arrive on shelves in January.
Patent applications have been submitted and are pending for both the new peptides and the delivery system found within the serum.
Additional workhorse components in the four-product line include rice proteins, a vitamin C antioxidant blend, hyaluronic acid and niacinamde.
Unlike retinoic acid, No7 says its new super peptide is both highly potent and highly tolerated, being suitable even for those with sensitive skin. This paves the way to highly effective skincare being available to even more people, according to the brand.
At AAD, Dr. Mike Bell, No7’s head of science research, hosted a special speaker session to showcase the peptide blend and the unique approach taken to identify bioactive naturally occurring peptides released from matrix degradation.
The novel matrix-derived peptide blend is the result of 15 years of research into skin aging and repair, according to the No7 team.
“We believe it is going to be a game changer for consumers,” Bell said.
No7 also shared details on the new skincare technology at the British Society for Investigative Dermatology (BSID) Annual Meeting which was held in Glasgow March 20 & 21.
The brand’s experts are also scheduled to present at the International Societies for Investigative Dermatology (ISID) meeting in Tokyo next month.
The line centers around a breakthrough super peptide created by No7 and the University of Manchester in the UK. The No7 team conducted blind clinical trials on the novel ingredient that No7 R&D contends “biohacks” the skin’s own natural repair process. The matrix-derived peptide blend contains two brand-new chemical entities, a patent-pending world-first technology that cannot be found in any other product, according to the brand.
Advanced mathematical modeling enabled the development of a potent delivery system that improves peptide penetration; the science has been confirmed through research with the University of Nottingham, according to No7.
Future Renew Damage Reversal Collection
The range includes Future Renew Damage Reversal Serum, which is said to reverse visible signs of skin damage in four weeks; Future Renew Damage Reversal Night Cream; Future Renew Damage Reversal Eye Serum; and Future Renew Damage Reversal Day Cream with SPF.The first three will hit shelves on April 12; the SPF will arrive on shelves in January.
Patent applications have been submitted and are pending for both the new peptides and the delivery system found within the serum.
Additional workhorse components in the four-product line include rice proteins, a vitamin C antioxidant blend, hyaluronic acid and niacinamde.
Unlike retinoic acid, No7 says its new super peptide is both highly potent and highly tolerated, being suitable even for those with sensitive skin. This paves the way to highly effective skincare being available to even more people, according to the brand.
Extensive Testing
The No7 team told Happi that the No7 Future Renew range has undergone the most extensive and diverse testing program in the brand’s history—37 studies on more than 4,200 people, including two clinical trials and 23 user trials. Fifty-one percent of the total testing group had skin of color, according to No. 7.No7 & The Dermatology Community
The No7 team provided early details to editors in February and showcased science behind the new line at the American Academy of Dermatology (AAD) Annual Conference last month in New Orleans. According to Kelli Hearst, No7’s global product director, the AAD conference was No7’s first-ever presence at an international scientific conference.At AAD, Dr. Mike Bell, No7’s head of science research, hosted a special speaker session to showcase the peptide blend and the unique approach taken to identify bioactive naturally occurring peptides released from matrix degradation.
The novel matrix-derived peptide blend is the result of 15 years of research into skin aging and repair, according to the No7 team.
“We believe it is going to be a game changer for consumers,” Bell said.
No7 also shared details on the new skincare technology at the British Society for Investigative Dermatology (BSID) Annual Meeting which was held in Glasgow March 20 & 21.
The brand’s experts are also scheduled to present at the International Societies for Investigative Dermatology (ISID) meeting in Tokyo next month.